87 related articles for article (PubMed ID: 2459780)
1. The role of interferons in the treatment of hematologic malignancies.
Gutterman JU
Semin Hematol; 1988 Jul; 25(3 Suppl 3):3-8. PubMed ID: 2459780
[TBL] [Abstract][Full Text] [Related]
2. Biotherapy with interferon--1988.
Figlin RA
Semin Oncol; 1988 Dec; 15(6 Suppl 6):3-9. PubMed ID: 2462749
[TBL] [Abstract][Full Text] [Related]
3. Biotherapy in clinical practice.
Figlin RA
Semin Hematol; 1989 Jul; 26(3 Suppl 3):15-24. PubMed ID: 2477904
[TBL] [Abstract][Full Text] [Related]
4. [Current status of interferon therapy].
Dittrich C
Wien Med Wochenschr; 1986 Apr; 136(7-8):163-72. PubMed ID: 2425497
[TBL] [Abstract][Full Text] [Related]
5. [Interferons. Treatment of malignant hemopathies with interferons].
Guilhot F; Sadoun A; Delwail V
Ann Med Interne (Paris); 1993; 144(8):548-56. PubMed ID: 7513980
[TBL] [Abstract][Full Text] [Related]
6. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S
Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976
[TBL] [Abstract][Full Text] [Related]
7. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
[TBL] [Abstract][Full Text] [Related]
9. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
10. [Interferon therapy in hematologic neoplasms].
Schwarzinger I; Bettelheim P; Lechner K
Wien Klin Wochenschr; 1988 Aug; 100(15):497-504. PubMed ID: 2459854
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
12. Biologic therapy of chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Gutterman J
Oncology (Williston Park); 1987 Sep; 1(7):35-40, 48-9, 52. PubMed ID: 3152810
[TBL] [Abstract][Full Text] [Related]
13. The role of interferons in the treatment of solid tumors.
Wadler S
Cancer; 1992 Aug; 70(4 Suppl):949-58. PubMed ID: 1379117
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
16. Intracellular cytokine analysis of interferon-gamma in T cells of patients with chronic myeloid leukemia.
Aswald JM; Lipton JH; Messner HA
Cytokines Cell Mol Ther; 2002 Dec; 7(2):75-82. PubMed ID: 12607798
[TBL] [Abstract][Full Text] [Related]
17. Current status of interferons in the treatment of cancer.
Hansen RM; Borden EC
Oncology (Williston Park); 1992 Nov; 6(11):19-24; discussion 26, 29. PubMed ID: 1280153
[TBL] [Abstract][Full Text] [Related]
18. [Clinical studies on interferon in cancer therapy in Japan].
Ohno R
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1194-202. PubMed ID: 2437862
[TBL] [Abstract][Full Text] [Related]
19. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
20. [Interferon-alpha in the treatment of hematologic neoplasms].
Aulitzky W; Gastl G; Tilg H; Troppmair J; Leiter E; Geissler D; Flener R; Huber C
Wien Med Wochenschr; 1986 Apr; 136(7-8):172-81. PubMed ID: 3524022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
